Obesity treatments using GLP-1 receptor agonists focus on weight management by promoting satiety, thereby reducing food intake and assisting in sustained weight loss
Considering that roughly one in eight adults worldwide currently live with obesity, the potential impact of these therapies is immense
"For consumers, the bottom line is simple: If a product claims to work 'just like a GLP-1 drug,' promises dramatic weight loss, or minimizes risk with slogans like 'all the benefits without the discomfort,' that should be a red flag," Ventura says
605 Aldose reductase inhibitor Ranirestat : Ranirestat is a potent aldose reductase inhibitor that reduces nerve sorbitol accumulation
Tony Mangubat and his team can assess your B12 status, identify the root cause of any deficiency, and recommend the treatment approach that matches your individual needs
[Its] unclear if it had an association with decreasing breast cancer recurrence risk